home | contact us

To be removed from the Early Stage East Mailing List, click here, and then click send in the e-mail window. Please note any forwards on your e-mail address in the body of the e-mail.

3 Mill Road, Suite 201A
Wilmington, DE 19806
Ph: 302.777.2460
Fax: 302.777.1620

Bio-Life-Tech 2004 Keynote Speakers

Breakfast Keynote Speaker
Dr. Elias A. Zerhouni
Director of the National Institutes of Health

Breakfast presented in partnership with

On May 20, 2002, Dr. Elias A. Zerhouni began his tenure as the 15th Director of the National Institutes of Health. Dr. Zerhouni initiated the creation of a new research vision for the NIH which focuses the attention of the biomedical research community on new pathways of discovery, research teams for the future and the re-engineering of the clinical research enterprise.

Among his noteworthy achievements since becoming Director, Dr. Zerhouni named directors for five institutes: National Institute of Mental Health, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke and National Institute of General Medical Sciences. He also named a new NIH Deputy Director, a new director of the Office of Technology Transfer, a new Deputy Director for Extramural Research, a new Associate Director for Budget, a new Deputy Director for Management and a new Associate Director of Communications. He has also overseen the completion of the doubling of the NIH budget.

Prior to joining the NIH, Dr. Zerhouni served as executive vice dean of Johns Hopkins University School of Medicine, chair of the Russell H. Morgan department of radiology and radiological science, and Martin Donner professor of radiology and professor of biomedical engineering.

His research in imaging led to advances in Computerized Axial Tomography (CAT scanning) and Magnetic Resonance Imaging (MRI) that resulted in 157 peer reviewed publications and 8 patents.

Since 2000, he has been a member of the National Academy of Sciences' Institute of Medicine. He served on the National Cancer Institute's Board of Scientific Advisors from 1998-2002.

Luncheon Keynote Speaker
C. Boyd Clarke
President and CEO, Neose Technologies

Luncheon presented in partnership with

Mr. Clarke provided the 2003 Bio-Life-Tech Conference Keynote Address, and his message was so powerful that, for the first time ever in Early Stage East's eight-year history, he returned, by popular demand, as the encore Keynote Speaker.

C. Boyd Clarke is president and chief executive officer of Neose Technologies, Inc. (Nasdaq: NTEC). He serves on the board of Neose, a biopharmaceutical company focused on the improvement of protein therapeutics through the application of its proprietary enzyme technologies for the synthesis and manufacture of complex carbohydrates. Mr. Clarke also serves on the Board of Directors of BIO (The Biotechnology Industry Organization).

The application of Neose's technologies to proteins potentially results in improved clinical activity and pharmacokinetic profile, enhanced drug development flexibility, stronger and additional patent claims, and yield improvements.

Neose currently has in place a co-development agreement with BioGenerix AG, a German biotech company that was founded in June 2000 by Ratiopharm Group, one of Europe's leading generic drug companies; a research partnership and licensing agreement with MacroGenics Inc.; and a licensing agreement for its technology with Novo Nordisk of Denmark.

Previously, Mr. Clarke was president, chief executive officer and chairman of Aviron, a biotechnology company developing vaccines, which was acquired by MedImmune, a company focused on using biotechnology to produce innovative products to impact patient health. In 2002, MedImmune acquired Aviron, now MedImmune Vaccines, which brought MedImmune vaccine technology and strengths that are synergistic with their established platform in infectious disease and immunology.

Mr. Clarke was also the chief executive officer and president of U.S. Bioscience, Inc., a biotechnology company focused on products to treat cancer, which was also acquired by MedImmune.

Mr. Clarke has held a number of positions at Merck & Co., Inc., including being the first president of Pasteur-Merieux MSD, and most recently as vice president of Merck Vaccines.

refund privacy disclaimer exhibitor guidelines